SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz among traders who are attracted to its active developer engagement and the community's push to build organic momentum, despite the project's early stage and lack of an official chart. Investors are actively discussing the potential for a significant breakout, emphasizing the need for sustained volume and broader social media promotion to move the token toward mainstream visibility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Guy is gaining traction as investors rally behind its status as an iconic, original meme, with the community actively promoting its restored meme-generation tools and historical roots on the Solana network. Supporters are focused on long-term conviction and 'bagwork,' positioning the token as a primary contender in the current meme coin cycle by emphasizing its deep cultural heritage and utility for content creation.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy (MULN CRYPTO) is currently trending as members debate its viability, with many in the community labeling it a pump-and-dump scheme or comparing it to the Mullen Automotive stock decline. While some users attempt to rally interest through community-led narratives and crypto-market speculation, others are actively warning investors to exit to avoid potential financial losses.

iShares Inc. - iShares MSCI Mexico ETF

iShares MSCI Mexico ETF

Investors are actively debating the long-term viability of Mexico as a manufacturing hub, with some noting its strategic importance in nearshoring supply chains while others warn of socio-economic decay and political risks. The community is focused on the impact of trade tariffs and US-Mexico relations on the performance of $EWW.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The XRP community remains deeply divided, with some investors accumulating tokens in anticipation of regulatory clarity and institutional adoption, while others express frustration over long-term price stagnation and perceived lack of progress. Debates are currently fueled by speculation surrounding the Clarity Act and the expansion of Ripple's payment infrastructure, leading to a polarized environment between optimistic long-term holders and disillusioned skeptics.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors monitor its development as a rare earth metals processor amid increasing urgency for U.S.-aligned supply chains. The community is actively debating the stock's long-term potential in the defense sector, with heavy discussions focused on the company's advisory board appointments, defense-related contracts, and the risks versus rewards associated with future production timelines.

Bitcoin SV (BSV) emerged following a hard fork of the Bitcoin Cash (BCH) blockchain in 2018, which had in turn forked from the BTC blockchain a year earlier. The goal of Bitcoin SV is to fulfil the original vision of the Bitcoin protocol and design as described in Satoshi Nakamoto’s white paper, early Bitcoin client software and known Satoshi writings. BSV aims to offer scalability and stability in line with the original description of Bitcoin as a peer-to-peer electronic cash system, as well as deliver a distributed data network that can support enterprise-level advanced blockchain applications. To this end, it has removed artificial block size limits and re-enabled Script commands and other technical capabilities which had been historically disabled or restricted by the protocol developers of the BTC blockchain. This allows the network to process tens of thousands of transactions per second while maintaining extremely low transaction fees for micropayments, in addition to offering advanced capabilities such as tokens, smart contracts, computation and other data use cases. The BSV network is unique in its capacity for unbounded on-chain scaling while also being more aligned with the original design of Bitcoin than any other blockchain.

Bitcoin SV

Bitcoin SV is facing significant volatility as the community reacts to ongoing court proceedings involving Craig Wright and his claims regarding the identity of Satoshi Nakamoto. Investors are debating the project's long-term utility and its role as the 'original protocol' versus the broader market dominance of BTC, with many tracking court updates as a key catalyst for potential price movements.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors due to clinical progress with its ITK inhibitor, soquelitinib, which has generated buzz for its potential to deliver durable, disease-modifying outcomes in atopic dermatitis and oncology. Community sentiment remains highly polarized, with intense debate between bulls anticipating a strategic buyout or short squeeze and skeptics emphasizing the inherent risks of a clinical-stage biotech and the potential for share dilution.

ETF Series Solutions - ESS U.S.Global Jets ETF

US Global Jets ETF

Airline stocks are facing renewed volatility as the sector grapples with potential operational disruptions, fuel cost pressures, and broader economic uncertainty. The community is actively debating the sustainability of travel demand and debating whether the recent price action offers a contrarian value opportunity or a warning of deeper industry headwinds.

Invesco Exchange-Traded Fund Trust II - Invesco Solar ETF

Invesco Solar ETF

Invesco Solar ETF is navigating heightened market volatility as investors weigh the impact of shifting political landscapes and policy rhetoric on long-term renewable energy demand. The community is actively debating the sector's resilience, with many pointing to the structural necessity of solar to support the power-intensive growth of AI and data center infrastructure despite short-term regulatory headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Year-ender 2025 view on Indian pharma achievements

2025 felt like a quiet reset for Indian pharma. Exports and policy support remained important, but the more meaningful shift was in what people focused on inside companies and hospitals, said Saransh Chaudhary, president, global critical care, Venus Remedies and chief executive, Venus Medicine Research Center in a personal view on the Indian pharmaceutical sector.

Bad drugs or no drugs: Cancer patients face scary reality tied to foreign supply chain

… shelves of pharmacies rooted in the production of drugs in India … U.S., supplied by Intas Pharmaceuticals , failed one out of … us inside the oncology pharmacy where the drugs that save his … broken system. -- Intas Pharmaceuticals and Venus Remedies did not …

SEBI-registered analyst <a href="https://stocktwits.com/STOCKCEPE">Gunjan Kumar</a> has flagged Ixigo and Venus Remedies as stocks with potential long-term growth.IxigoKumar noted that Ixigo is nearly debt-free and has seen increased investment from domestic institutional investors (DII) in the past quarter, signaling growing investor confidence.<stembedurl>https://stocktwits.com/STOCKCEPE/message/617962420</stembedurl>The analyst said the strong demand from Tier II and III cities, where Ixigo enjoys a 94% penetration rate, is fueling the company’s growth.The company is now ramping up investment in hotel bookings to boost revenue, inspired by the success of its competitors.With India’s travel market projected to reach $48 billion by 2027, supported by rising incomes and improved infrastructure, Ixigo is well-positioned for sustained growth, according to Kumar.Technically, the stock recently broke resistance, closing above ₹185 for the first time. Kumar suggests watching for a move above ₹192, with support at ₹169.On the financial front, it has reported record-high revenue and over 70% year-on-year sales growth since its IPO.Venus RemediesVenus Remedies has an attractive valuation, according to Kumar. The company exports to over 70 countries and operates in a sector poised for growth.<stembedurl>https://stocktwits.com/symbol/VENUSREM.NSE</stembedurl>India’s pharmaceutical industry is expected to reach $65 billion by 2024, growing at 10–12% annually, driven mainly by demand for generic drugs.Fundamentally, Venus Remedies is almost debt-free and recently posted its highest net profit in the last 13 quarters, with revenue figures in line with the same quarter the previous year.The analyst said that foreign institutional investors (FIIs) have steadily increased their stakes over the past four quarters, signaling growing confidence in the company’s long-term prospects.From a technical perspective, the stock has broken out of a multi-year resistance zone and successfully retested it.The analyst suggested watching for ₹475 on the upside, with support at ₹424 on a closing basis.For updates and corrections, email newsroom[at]stocktwits[dot]com.

(Photo credit should read INDRANIL MUKHERJEE/AFP via Getty Images)

Ixigo And Venus Remedies Show Long-term Upside Potential: SEBI RA Gunjan Kumar 

The analyst eyes breakout opportunities in these two stocks, driven by their technical strength and growing institutional interest.

Equity

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

… or Sanofi , while one brand, Huminsulin by US-based pharma giant Eli Lilly , … care) of research-driven pharma company Venus Remedies. Innovative … case of small molecule drugs —have now hit the … “The entry of multiple pharmaceutical companies into this space …

Medivirs CEO to BioStock: I am proud to see our research contribute to a global solution

Antibiotic resistance is a growing global crisis, increasing the urgency for effective treatments. While Medivir now focuses on cancer therapies, it has a legacy in antimicrobial research. This was highlighted by Infex Therapeutics licensing agreement with Venus Remedies Ltd for the development of MET-X in India a compound developed from a research program that Medivir outlicensed in 2017. We reached out to Medivirs CEO Jens Lindberg for a comment. Read the interview with Jens Lindberg at biostock.se: https://www.biostock.se/en/2025/03/medivirs-ceo-i-am-proud-to-see-our-research-

India, EU to renew FTA negotiations

India and the European Union will this week take stock of their negotiations for an ambitious free trade deal and broadly firm up a new strategic agenda. Venus Remedies inks pact with UK firm New Delhi: Venus Remedies said it has joined hands with UK-based Infex Therapeutics for the development of MET-X, an inhibitor, to […]

Venus Remedies Ltd. engages in the manufacture and trade of pharmaceutical products. Its products include analgesic, analgesic and antipyretic, anti diabetic, antibiotic, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizer, hormone, iron supplement, neurology, oncology, pain management, respiratory, skin care, stress reliever, urology, vitamins/minerals/nutrients, and wound management. The company was founded by Pawan Chaudhary on September 15, 1989 and is headquartered in Panchkula, India.

VENUSREM.NSE
Venus Remedies Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest VENUSREM.NSE News

VENUSREM.NSEVenus Remedies Ltd.